A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

A Three-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-drug Interactions (DDIs) Between DBPR108 and Warfarin Sodium/Digoxin/Probenecid in Healthy Subjects

This is a three-part, single-center, open-label phase I clinical study to characterize the DDIs potential of DBPR108 with Warfarin sodium, Digoxin, or Probenecid in healthy subjects. This study also aims to evaluate the safety and tolerability of DBPR108 in the presence of Warfarin sodium, Digoxin, or Probenecid.

Study Overview

• Status: Completed
• Conditions: Healthy Subjects
• Intervention / Treatment: Drug: DBPR108 tablets; Drug: Warfarin sodium tablets; Drug: Digoxin tablet; Drug: Probenecid tablets

Detailed Description

DBPR108 is a potent dipeptidylpeptidase-4 inhibitor. This study will be run in three parts to characterize the DDIs potential of DBPR108 with the expected concomitant drugs (Warfarin sodium, Digoxin, Probenecid) in Healthy Subjects. Each part of this study consists of a screening period (Day -14 to Day -1), a baseline period (Day -1), a treatment period, and a follow-up visit period. Approximately 14 subjects will be enrolled in each part of this study.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Suzhou, China
    • First Affiliated Hospital of Soochow University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;
2. 18 to 45 years (inclusive), male and female;
3. Male subjects weight ≥50.0 kg and female subjects weight ≥45.0 kg. Body mass index (BMI): 18-28 kg/m^2 (inclusive) (BMI= weight (kg)/height^2 (m^2)；
4. Subjects (including their partners) are willing to use effective contraceptives from screening to the 6 months after the last dose administration;
5. Subjects judged to be in good health by the investigator, based on the physical examination, vital signs examination, 12-lead electrocardiogram (ECG) examination and laboratory examination etc;

Exclusion Criteria:

1. Subjects who have a history of allergic conditions (such as asthma, urticaria), or have a history of allergy to any of the study drugs or other similarly structured drugs;
2. Subjects with a history of severe diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematological, psychiatric/neurological systems diseases within 1 year prior to screening;
3. Subjects with a history of hypoglycemia or abnormal blood glucose at screening: fasting blood glucose <70 mg/dL (3.9 mmol/L) or >110 mg/dL (6.1 mmol/L);
4. Subjects who have previously undergone surgery that may affect the absorption, distribution, metabolism, or excretion of the drug (e.g., subtotal gastrectomy), or who have a scheduled surgical plan during the study period;
5. Use of any prescription drug, over-the-counter drug, or herbal medicine within 2 weeks prior to screening;
6. Have been vaccinated within 4 weeks prior to screening or who have a scheduled vaccinated plan during the study period;
7. History of drug abuse, or positive urine drug screen at screening;
8. Smoking more than 5 cigarettes per day within 3 months prior to screening，or who cannot stop using any tobacco products during the study period；
9. Average daily intake of alcohol is more than 28 g alcohol (male) or 14 g (female) (14 g ≈ 497 mL beer, or 44 mL spirits with low alcohol content, or 145 mL wine) within the 3 months prior to screening, or taking any product containing alcohol within 48 h before dosing, or a positive ethanol breath test at screening;
10. Consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) within 48 h before the administration, or those who have had strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, etc;
11. Participation in another clinical trial within 3 months before screening (whichever is administrated)；
12. Blood donation (or blood loss) ≥400 mL, or receiving whole blood transfusions or erythrocyte suspension transfusions within 3 months prior to the screening;
13. Any positive test result of hepatitis B surface antigen, hepatitis C virus antibody, anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific antibody;
14. Pregnant/lactating woman, or has a positive pregnancy test at screening;
15. Not suitable for this study as judged by the investigator;
16. Supplementary exclusion criteria for the first part of the study: subjects with bleeding tendency, or PT and INR test results judged by the investigator to be not suitable for participating in the study;
17. Supplementary exclusion criteria for the third part of the study: the estimated glomerular filtration rate (eGFR) calculated by the modification of diet in renal diseases (MDRD) equation at screening with clinical significance as judged by the investigator, or subjects with nephrolithiasis or have a history of nephrolithiasis.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: The DDI of DBPR108 and Warfarin Sodium Tablets; Subjects will receive a single dose of Warfarin sodium 5 mg on Day 1, then take DBPR108 100 mg once-daily on Day 15 through Day 26 and a single dose of Warfarin sodium 5 mg on Day 19.	Drug: DBPR108 tablets; Drug: DBPR108, tablet, oral; Other Names: DBPR108; Drug: Warfarin sodium tablets; Drug: Warfarin sodium, tablet, oral
EXPERIMENTAL: The DDI of DBPR108 and Digoxin Tablets; Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take DBPR108 100 mg once-daily on Day 6 through Day 15 and a single dose of Digoxin 0.25 mg on Day 10.	Drug: DBPR108 tablets; Drug: DBPR108, tablet, oral; Other Names: DBPR108; Drug: Digoxin tablet; Drug: Digoxin, tablet, oral
EXPERIMENTAL: The DDI of DBPR108 and Probenecid Tablets; Subjects will receive a single dose of DBPR108 100 mg on Day 1, then take Probenecid 500 mg twice-daily on Day 5 through Day 9 and a single dose of DBPR108 100 mg on Day 7.	Drug: DBPR108 tablets; Drug: DBPR108, tablet, oral; Other Names: DBPR108; Drug: Probenecid tablets; Drug: Probenecid, tablet, oral

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Part one: Peak plasma concentration (Cmax) of S-warfarin and R-warfarin	Day 1 to Day 8, and Day 19 to Day 26
Part one: Area under the plasma concentration versus time curve (AUC) of S-warfarin and R-warfarin	Day 1 to Day 8, and Day 19 to Day 26
Part one: Peak plasma concentration (Cmax) of DBPR108	Day 17 to Day 20
Part one: Area under the plasma concentration versus time curve (AUC) of DBPR108	Day 17 to Day 20
Part two: Peak plasma concentration (Cmax) of Digoxin	Day 1 to Day 6, and Day 10 to Day 15
Part two: Area under the plasma concentration versus time curve (AUC) of Digoxin	Day 1 to Day 6, and Day 10 to Day 15
Part two: Peak plasma concentration (Cmax) of DBPR108	Day 8 to Day 11
Part two: Area under the plasma concentration versus time curve (AUC) of DBPR108	Day 8 to Day 11
Part three: Peak plasma concentration (Cmax) of DBPR108	Day 1 to Day 3, and Day 7 to Day 9
Part three: Area under the plasma concentration versus time curve (AUC) of DBPR108	Day 1 to Day 3, and Day 7 to Day 9

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part one: Time to achieve maximum plasma concentration (Tmax) of S-warfarin and R-warfarin		Day 1 to Day 8, and Day 19 to Day 26
Part one: Half-life(t1/2) of S-warfarin and R-warfarin		Day 1 to Day 8, and Day 19 to Day 26
Part one: Apparent volume of Distribution(Vz/F) of S-warfarin and R-warfarin		Day 1 to Day 8, and Day 19 to Day 26
Part one: Apparent clearance(CL/F) of S-warfarin and R-warfarin		Day 1 to Day 8, and Day 19 to Day 26
Part one: Time to achieve maximum plasma concentration (Tmax) of DBPR108		Day 17 to Day 20
Part one: Half-life(t1/2) of DBPR108		Day 17 to Day 20
Part one: Apparent volume of Distribution(Vz/F) of DBPR108		Day 17 to Day 20
Part one: Apparent clearance(CL/F) of DBPR108		Day 17 to Day 20
Part one: the pharmacodynamic parameters-Prothrombin time(PT)		Day 1 to Day 8, and Day 19 to Day 26
Part one: the pharmacodynamic parameters-International normalized ratio(INR)		Day 1 to Day 8, and Day 19 to Day 26
Part two: Time to achieve maximum plasma concentration (Tmax) of Digoxin		Day 1 to Day 6, and Day 10 to Day 15
Part two: Half-life(t1/2) of Digoxin		Day 1 to Day 6, and Day 10 to Day 15
Part two: Apparent volume of Distribution(Vz/F) of Digoxin		Day 1 to Day 6, and Day 10 to Day 15
Part two: Apparent clearance(CL/F) of Digoxin		Day 1 to Day 6, and Day 10 to Day 15
Part two: Time to achieve maximum plasma concentration (Tmax) of DBPR108		Day 8 to Day 11
Part two: Half-life(t1/2) of DBPR108		Day 8 to Day 11
Part two: Apparent volume of Distribution(Vz/F) of DBPR108		Day 8 to Day 11
Part two: Apparent clearance(CL/F) of DBPR108		Day 8 to Day 11
Part three: Time to achieve maximum plasma concentration (Tmax) of DBPR108		Day 1 to Day 3, and Day 7 to Day 9
Part three: Half-life(t1/2) of DBPR108		Day 1 to Day 3, and Day 7 to Day 9
Part three: Apparent volume of Distribution(Vz/F) of DBPR108		Day 1 to Day 3, and Day 7 to Day 9
Part three: Apparent clearance(CL/F) of DBPR108		Day 1 to Day 3, and Day 7 to Day 9
Part three:Cumulative amount of drug excreted in urine(Ae) of DBPR108		Day 1 to Day 3, and Day 7 to Day 9
Part three: Cumulative fraction of the dose excreted(fe) of DBPR108		Day 1 to Day 3, and Day 7 to Day 9
Part three: Renal Clearance(CLR) of DBPR108		Day 1 to Day 3, and Day 7 to Day 9
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Number of participants with treatment-related adverse events will be assessed by CTCAE v5.0. The AEs will be summarized according to the system organ class (SOC) and preferred term (PT), including the number and percentage of participants who had AEs.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in 12-lead electrocardiogram (ECG) examination will be recorded as AEs at each visit time point.	ECG monitoring includes heart rate in bpm.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in 12-lead electrocardiogram (ECG) examination will be recorded as AEs at each visit time point.	ECG monitoring includes P-R, QT and QTc intervals in ms.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in physical examination will be recorded as AEs at each visit time point.	Physical examination includes general conditions, skin, mucous membranes, head, neck, chest, abdomen, spine, limbs, nervous system, and lymphatic system.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point.	Vital signs monitoring includes body temperature in degrees Celsius.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point.	Vital signs monitoring includes respiratory rate and pulse in times per minute.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point.	Vital signs monitoring includes systolic blood pressure and diastolic blood pressure in mmHg.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in routine blood test will be recorded as AEs at each visit time point.	Routine blood test includes red blood cell count in 10^12/L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in routine blood test will be recorded as AEs at each visit time point.	Routine blood test includes hemoglobin in g/L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in routine blood test will be recorded as AEs at each visit time point.	Routine blood test includes hematocrit in L/L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in routine blood test will be recorded as AEs at each visit time point.	Routine blood test includes white blood cell count, platelet, neutrophilic granulocyte count, lymphocyte count and monocyte count in 10^9 /L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.	Blood biochemistry test includes total protein and albumin in g/L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.	Blood biochemistry test includes alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and glutamyltranspeptidase in U/L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.	Blood biochemistry test includes total bilirubin and serum creatinine in umol/L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.	Blood biochemistry test includes urea in mmol/L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point.	Routine urine test includes urobilinogen, glucose and protein in mg/dL.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point.	Routine urine test includes pH.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in coagulation function test will be recorded as AEs at each visit time point.	Coagulation action test includes fibrinogen in g/L.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in coagulation function test will be recorded as AEs at each visit time point.	Coagulation action test includes prothrombin time, thrombin time and activated partial thromboplatin time in seconds.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.
Clinically significant changes from baseline in coagulation function test will be recorded as AEs at each visit time point.	Coagulation action test includes international normalized ratio.	Up to Day 33 from screening for part one, up to Day 22 from screening for part two, and up to Day 16 from screening for part three.

Collaborators and Investigators

• Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 20, 2021
• Primary Completion (ACTUAL): December 1, 2021
• Study Completion (ACTUAL): December 1, 2021

Study Registration Dates

• First Submitted: August 5, 2021
• First Submitted That Met QC Criteria: September 6, 2021
• First Posted (ACTUAL): September 16, 2021

Study Record Updates

• Last Update Posted (ACTUAL): March 10, 2022
• Last Update Submitted That Met QC Criteria: March 9, 2022
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Enzyme Inhibitors; Antirheumatic Agents; Protective Agents; Cardiotonic Agents; Anticoagulants; Gout Suppressants; Renal Agents; Uricosuric Agents; Digoxin; Warfarin; Probenecid
• Other Study ID Numbers: HA1118-CSP-012

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No